The Human Plasma and Serum Proteome

  • Gilbert S. Omenn
  • Rajasree Menon
  • Marcin Adamski
  • Thomas Blackwell
  • Brian B. Haab
  • Weimin Gao
  • David J. States


Human plasma and serum are the preferred specimens for noninvasive studies of normal and disease-associated proteins in the circulation and arising from cells throughout the body. The attributes of extreme complexity, very wide dynamic range, genetic and physiological variation, endogenous and ex vivo modifications, and incompleteness of sampling by mass spectrometry all represent major challenges to reproducible, high-resolution, high-throughput analyses of the plasma proteome. This chapter summarizes the major reports to date identifying proteins in normal individuals and identifies paths to increased use of proteomics methods with human specimens for biomarker discovery and application in various diseases.

Key Words

Plasma proteome complexity dynamic range abundance variation posttranslational modifications splice isoforms ex vivo modification high-throughput error estimation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226–3245. Also, Omenn GS. Exploring the Human Plasma Proteome. Wiley-Liss, 2006.PubMedCrossRefGoogle Scholar
  2. 2.
    Ping P, Vondriska TM, Creighton CJ, et al. A functional annotation of subproteomes in human plasma. Proteomics 2005;5:3506–3519.PubMedCrossRefGoogle Scholar
  3. 3.
    Putnam FW. The Plasma Proteins: Structure, Function, and Genetic Control. New York: Academic, 1975.Google Scholar
  4. 4.
    Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1.11:845–867.PubMedCrossRefGoogle Scholar
  5. 5.
    Echan LA, Tang H-Y, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high abundance proteins improves protein profiling capacities of human serum and plasma Proteomics 2005;5:3292–3303.PubMedCrossRefGoogle Scholar
  6. 6.
    Rhodes DR, Tomlins SA, Varambally S, et al. Comprehensive model of the human protein-protein interaction network. Comput Biol 2005;8:1–9.Google Scholar
  7. 7.
    Peri S, Navarro JD, Amanchy R, et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003;13:2363–2371.PubMedCrossRefGoogle Scholar
  8. 8.
    Mann M, Aebersold R. Mass spectrometry-based proteomics. Nature 2003; 422;198–207.PubMedCrossRefGoogle Scholar
  9. 9.
    Sadygov R, Yates JR. A hypergeometric probability model for protein identification and validation using tandem mass spectral data and protein sequence databases. Anal Chem 2003;75:3792–3798.Google Scholar
  10. 10.
    Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74:5383–5392.PubMedCrossRefGoogle Scholar
  11. 11.
    Nesvizhskii AI, Keller A, Kolker E, et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:4646–4658.PubMedCrossRefGoogle Scholar
  12. 12.
    Cargile BJ, Bundy JL, Stephenson JL, Jr. Potential for false positive identifications from large databases through tandem mass spectrometry. J Proteome Res 2004;3:1082–1085.PubMedCrossRefGoogle Scholar
  13. 13.
    Kapp EA, Schutz F, Connolly LM, et al. An evaluation, comparison and accurate benchmarking of several publicly-available MS/MS search algorithms: sensitivity and specificity analysis. Proteomics 2005;5:3475–3490.PubMedCrossRefGoogle Scholar
  14. 14.
    Johnson RS, Davis MT, Taylor JA, Patterson SD. Informatics for protein identification by mass spectrometry. Methods 2005;35:223–236.PubMedCrossRefGoogle Scholar
  15. 15.
    Marshall J, Kupchak P, Zhu W, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361–372.PubMedCrossRefGoogle Scholar
  16. 16.
    Rai AJ, Gelfand CA, Haywood BC, et al. Human Proteome Organization—Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005;5:3262–3277.PubMedCrossRefGoogle Scholar
  17. 17.
    Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311–316.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang H, Clouthier SG, Galchev V, et al. Intact-protein based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005;4:618–625.PubMedCrossRefGoogle Scholar
  19. 19.
    Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994–999.PubMedCrossRefGoogle Scholar
  20. 20.
    Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3:1154–1169.PubMedCrossRefGoogle Scholar
  21. 21.
    Kuster B, Schirle M, Mallick P, Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat Rev Mol Cell Biol 2005;6:577–583.PubMedCrossRefGoogle Scholar
  22. 22.
    Craig R, Cortens UJP, Beavis RC. The use of proteotypic peptide libraries for protein identification. Rapid Commun Mass Spectrom 2005;19:1844–1850.PubMedCrossRefGoogle Scholar
  23. 23.
    Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005;1:252–262.PubMedCrossRefGoogle Scholar
  24. 24.
    Haab B. Methods and applications of antibody microarrays in cancer research. Proteomics 2003;3:2116–2122.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhu H, Bilgin M, Bangham R, et al. Global analysis of protein activities using proteome chips. Science 2001;293:2101–2105.PubMedCrossRefGoogle Scholar
  26. 26.
    Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–577.PubMedCrossRefGoogle Scholar
  27. 27.
    Rai AJ, Stemmer PM, Zhang Z, et al. Analysis of HUPO PPP reference specimens using SELDI-TOF mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005;5:3467–3474.PubMedCrossRefGoogle Scholar
  28. 28.
    Pieper R, Gatlin CL, Makusky AJ, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003;3:1345–1364.PubMedCrossRefGoogle Scholar
  29. 29.
    Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002;1:947–952.PubMedCrossRefGoogle Scholar
  30. 30.
    Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096–1103.PubMedCrossRefGoogle Scholar
  31. 31.
    Shen Y, Jacobs JM, Camp DG II, et al. Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal Chem 2004;76:1134–1144.PubMedCrossRefGoogle Scholar
  32. 32.
    Shen Y, Smith RD. Advanced nanoscale separations and mass spectrometry for sensitive high-throughput proteomics. Expert Rev Proteomics 2005;2:431–447.PubMedCrossRefGoogle Scholar
  33. 33.
    Chan KC, Lucas DA, Hise D, et al. Analysis of the human serum proteome. Clin Proteomics 2004;1:101–226.CrossRefGoogle Scholar
  34. 34.
    Zhou M, Lucas DA, Chan KC, et al. An investigation in the human serum interactome. Electrophoresis 2004;25:1289–1298PubMedCrossRefGoogle Scholar
  35. 35.
    Rose K, Bougueleret L, Baussant T, et al., Industrial-scale proteomics: from liters of plasma to chemically synthesized proteins. Proteomics 2004;4:2125–2150.PubMedCrossRefGoogle Scholar
  36. 36.
    Hanash SM, Celis JE. The Human Proteome Organization: a mission to advance proteome knowledge. Mol Cell Proteomics 2002;1:413–414.PubMedCrossRefGoogle Scholar
  37. 37.
    Omenn GS. The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004;4:1235–1240.PubMedCrossRefGoogle Scholar
  38. 38.
    Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E, Apweiler, R. The International Protein Index: an integrated database for proteomics experiments. Proteomics 2004;4:1985–1988. Scholar
  39. 39.
    Adamski M, States DJ, Omenn GS. Data standardization and integration in collaborative proteomics studies. In: Srivastava S, ed. Informatics in Proteomics. New York: Marcel Dekker, 2004:169–194.Google Scholar
  40. 40.
    Adamski M, Blackwell T, Menon R, et al. Data management and preliminary data analysis in the pilot phase of the HUPO Plasma Proteome Project. Proteomics 2005;5:3246–3261.PubMedCrossRefGoogle Scholar
  41. 41.
    Carr S, Aebersold R, Baldwin M. The need for guidelines in publication of peptide and protein identification data. Mol Cell Proteomics 2004;3:351–353.Google Scholar
  42. 42.
    States DJ, Omenn GS, Blackwell TW, et al. Deriving high confidence protein identifications from a HUPO collaborative study of human serum and plasma. Nat Biotechnol 2006;24:333–338.PubMedCrossRefGoogle Scholar
  43. 43.
    Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660–666.PubMedCrossRefGoogle Scholar
  44. 44.
    Yang Z, Hancock WS, Richmond-Chew T, Bonilla L. A Study of glycoproteins in human serum and plasma reference standards (HUPO) using multi-lectin affinity chromatography coupled with RPLC-MS/MS. Proteomics 2005;5:3353–3366.PubMedCrossRefGoogle Scholar
  45. 45.
    Tang HY, Ali-Khan N, Echan LA, et al. A novel 4-dimensional strategy combining protein and peptide separation methods enables detection of low abundance proteins in human plasma and serum proteomes. Proteomics 2005;5:3329–3342.PubMedCrossRefGoogle Scholar
  46. 46.
    Haab BB, Geierstanger BH, Michailidis G, et al. Immunoassay and antibody microarray analysis of the HUPO PPP reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005;5:3278–3291.PubMedCrossRefGoogle Scholar
  47. 47.
    Muthasamy B, Hanumanthu G, Reshmi R, et al. Plasma proteome database as a resource for proteomics research. Proteomics 2005;5:3531–3536.CrossRefGoogle Scholar
  48. 48.
    Berhane BT, Zong C, Liem, et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005;5:3520–3530.PubMedCrossRefGoogle Scholar
  49. 49.
    Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414–3422.PubMedCrossRefGoogle Scholar
  50. 50.
    Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271–284.PubMedCrossRefGoogle Scholar
  51. 51.
    Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:226–230.Google Scholar
  52. 52.
    Uhlen M, Ponten F. Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 2005;4.4:384–393.PubMedCrossRefGoogle Scholar
  53. 53.
    Hanash S. Harnessing immunity for disease proteomics. Nat Biotechnol 2003;21:37–38.PubMedCrossRefGoogle Scholar
  54. 54.
    Imafuku Y, Omenn GS, Hanash S. Proteomics approaches to identify auto-immune antibodies as cancer biomarkers. Dis Markers 2004;20:149–153.PubMedGoogle Scholar
  55. 55.
    Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224–1235.PubMedCrossRefGoogle Scholar
  56. 56.
    Gao WM, Kuick R, Orchekowski RP, et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005;5:110.PubMedCrossRefGoogle Scholar
  57. 57.
    Hong SH, Misek DE, Wang H, et al. Auto-antibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004;64:5504–5510.PubMedCrossRefGoogle Scholar
  58. 58.
    Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97:315–319.PubMedCrossRefGoogle Scholar
  59. 59.
    Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882–5890.PubMedCrossRefGoogle Scholar
  60. 60.
    Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102–112.PubMedCrossRefGoogle Scholar
  61. 61.
    Bouwman K, Qiu J, Zhou H, et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003;3:2200–2207.PubMedCrossRefGoogle Scholar
  62. 62.
    Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261–267.PubMedCrossRefGoogle Scholar
  63. 63.
    Espina V, Woodhouse EC, Wulfkuhle J, et al. Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods 2004;290:121–133.PubMedCrossRefGoogle Scholar
  64. 64.
    Barker PE, Wagner PD, Stein SE, Bunk DM, Srivastava S, Omenn GS. Standards for plasma and serum proteomics in early cancer detection: a needs assessment from the NIST-NCI SMART workshop. Clin Chem 2006;52:1669–1674.PubMedCrossRefGoogle Scholar
  65. 65.
    Keller A, Purvine S, Nesvizhskii AI, Stolyar S, Goodlett DR, Kolker E. Experimental protein mixture for validating tandem mass spectral analysis OMICS. J Integr Biol 2002;6:207–212.CrossRefGoogle Scholar
  66. 66.
    Strahler JR, Veine D, Walker A, et al. A publicly available dataset of MALDI-TOF/TOF and LTQ mass spectra of known proteins ASMS Session 2005: Bioinformatics Code: TP22 Time Slot/Poster Number: 398.Google Scholar
  67. 67.
    Nesvizhskii AI, Aebersold R. Interpretation of shotgun proteomic data-the protein inference problem. Mol Cell Proteomics 2005;4.10:1419–1440.PubMedCrossRefGoogle Scholar
  68. 68.
    Rauch A, Bellew M, Eng J, et al. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 2006;5:112–121.PubMedCrossRefGoogle Scholar
  69. 69.
    Omenn GS. Strategies for proteomics profiling of human tumors. Proteomics 2006;6:5662–5673.PubMedCrossRefGoogle Scholar
  70. 70.
    Adkins JN, Monroe ME, Auberry KJ, et al. A proteomic study of HUPO’s Plasma Proteome Project pilot samples using an accurate mass and time tag strategy. Proteomics 2005;5:3454–3466.PubMedCrossRefGoogle Scholar
  71. 71.
    Olsen JV, Mann M. Improved peptide identification in proteomics by two consecutive stages of mass spectrometric fragmentation. Proc Natl Acad Sci U S A 2004; 101:13,417–13,422.PubMedCrossRefGoogle Scholar
  72. 72.
    Humphery-Smith I. A human proteome project with a beginning and an end. Proteomics 2004;4:2519–2521.PubMedCrossRefGoogle Scholar
  73. 73.
    Aebersold R. Constellations in a cellular universe. Nature 2003;422:115–116.PubMedCrossRefGoogle Scholar
  74. 74.
    Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5(4):573–588.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Authors and Affiliations

  • Gilbert S. Omenn
    • 1
  • Rajasree Menon
    • 2
  • Marcin Adamski
    • 2
  • Thomas Blackwell
    • 2
  • Brian B. Haab
    • 3
  • Weimin Gao
    • 4
  • David J. States
    • 5
  1. 1.Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and Biology, Departments of Internal Medicine and Human GeneticsUniversity of Michigan Medical SchoolAnn Arbor
  2. 2.Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and BiologyUniversity of Michigan Medical SchoolAnn Arbor
  3. 3.Michigan Proteomics Alliance for Cancer ResearchVan Andel Research InstituteGrand Rapids
  4. 4.Michigan Proteomics Alliance for Cancer ResearchUSA
  5. 5.Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and Biology, Department of Human GeneticsUniversity of Michigan Medical SchoolAnn Arbor

Personalised recommendations